DVL1 and neuroendocrine neoplasm: These data also suggest that treatment of neuroendocrine tumors with pan-Dvl PDZ domain or CK1δ/ε inhibitors might be viable options to enhance Sstr2 expression and potentiate Sstr2-directed cytotoxic therapies.